Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

Since the announcements by federal health authorities earlier this year that federal mRNA vaccine funding will be curtailed, ...

Moderna MRNA announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in ...

Moderna will get $54M from a global coalition for a bird flu mRNA vaccine after the US canceled a $760M deal and cut mRNA ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 bird flu vaccine candidate, mRNA-1018. See our latest analysis for Moderna.

Can the weakened immune systems of older individuals be rejuvenated? Researchers from the German Cancer Research Center (DKFZ ...

SMRTS, a smart mRNA system, enables cell‑selective gene expression, expanding the mRNA toolbox for precision cancer therapies.